India  

COVID-19 vaccine: Bharat Biotech's Covaxin Phase 1 trial shows it has no serious adverse events

DNA Wednesday, 16 December 2020
COVID-19 vaccine: Bharat Biotech's Covaxin Phase 1 trial shows it has no serious adverse eventsPain at the injection site was the most common local adverse event and was well tolerated in all dose groups.
0
shares
ShareTweetSavePostSend
 
Video Credit: HT Digital Content - Published
News video: Covid-19 positive Anil Vij shifted to Rohtak hospital, condition stable

Covid-19 positive Anil Vij shifted to Rohtak hospital, condition stable 03:32

Haryana Health Minister Anil Vij, who tested positive for Covid-19, has been shifted to Rohtak's PGIMS hospital. Vij was earlier admitted to the civil hospital in Ambala. He was reportedly shifted on Saturday night after he had complained of discomfort. Hospital authority said Vij's condition is...

You Might Like


Related videos from verified sources

Bharat Biotech seeks emergency use approval for Covid-19 vaccine Covaxin | Oneindia News [Video]

Bharat Biotech seeks emergency use approval for Covid-19 vaccine Covaxin | Oneindia News

Now after Serum Institute of India and American pharma giant Pfizer, Bharat Biotech, the Hyderabad-based pharmaceutical firm that has been developing coronavirus vaccine Covaxin, has applied to the..

Credit: Oneindia     Duration: 01:08Published
Anil Vij tests Covid positive, was given trial dose of Covaxin last month [Video]

Anil Vij tests Covid positive, was given trial dose of Covaxin last month

Haryana health minister Anil Vij tested positive for Covid-19. Vij has been admitted to Civil Hospital Ambala Cantt. Vij tweeted, “I have been tested Corona positive. I am admitted in Civil Hospital..

Credit: HT Digital Content     Duration: 01:38Published
CM Yediyurappa launches phase-3 trials of Covaxin in Bengaluru [Video]

CM Yediyurappa launches phase-3 trials of Covaxin in Bengaluru

Karnataka Chief Minister BS Yediyurappa virtually inaugurated phase-3 clinical trials of 'Covaxin' (COVID-19 vaccine), which is being developed by Bharat Biotech in collaboration with Indian Council of..

Credit: ANI     Duration: 02:23Published

Related news from verified sources

Bharat Biotech’s Covaxin ‘well tolerated with no serious adverse events’

The findings of phase 1 clinical trial of the COVID-19 vaccine have appeared on medRxiv, a preprint server.
Hindu

Covaxin induced robust immune response in Phase 1 trials: Bharat Biotech

India’s first indigenous vaccine Covaxin was successful in inducing a robust immune response without any serious adverse events during the Phase 1 trials that...
IndiaTimes